Berlin-based Aignostics, a global AI company that turns complex multi-modal pathology data into transformative insights, announced on Tuesday that it has raised $34M (approximately €31M) in Series B funding.
The oversubscribed funding round was led by ATHOS, with investments from Mayo Clinic and growth financing from HTGF, alongside support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie managed by IBB Ventures.
To date, the German company has raised over $55M (approximately €50M).
Fund utilisation
The new funding will help the German company to improve its work in target identification, translational research, and companion diagnostics (CDx).
The capital will also support other significant initiatives, including:
Launching easy-to-use products for different applications, like tumor microenvironment analysis and biomarker profiling.
Expanding in the US by hiring more staff and supporting US partners.
Working together with the Mayo Clinic to develop core models and biopharma products.
“2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV,” says Viktor Matyas, CEO and Co-Founder of Aignostics.
“With RudolfV, we’ve gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world. Now with this new round of funding, we’re turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology,” adds Matyas.
As precision medicine becomes more complex, biopharmaceutical companies are using AI to improve how they analyse pathology for drug development and diagnostics.
Aignostics: Turning complex multimodal pathology data into insights
Founded in 2018 as a spin-off from Charité Berlin, Aignostics is an artificial intelligence (AI) company that turns complex multimodal pathology data into transformative insights.
Aignostics uses a variety of clinical data, technology, and scientific methods to develop products and services for precision medicine.
Through collaborations with its biopharma partners, the German company supports drug discovery, translational research, clinical trials, and CDx development.
The investor
ATHOS is a single-family office that supports entrepreneurs to positively impact health and well-being. The company is a long-term majority investor in BioNTech.
“At its core, Aignostics is a world-class machine learning company,” says Julian Zachmann from ATHOS.
“The field is advancing so quickly that, to succeed, AI companies need to avoid flashy distractions, stay laser-focused on the highest-quality science, and relentlessly innovate. Aignostics is doing just that and bringing a level of transparency and rigor to its biopharmaceutical clients that we think is truly unique,” adds Zachmann.
HTGF is an early-stage investor in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences, and Chemistry.
HTGF invests in the pre-seed and seed phase and can participate significantly in further financing rounds, since 2024 with the HTGF Opportunity growth fund. Across its funds, HTGF has over €2B under management.
Since its inception in 2005, HTGF has financed more than 750 startups and successfully sold shares in more than 180 companies.
Niels Sharman, Senior Investment Manager at HTGF, says, “We have been thoroughly impressed by Aignostics’ progress and their cutting-edge AI platform, which we believe will have a transformative impact on Pharma R&D. It is a pleasure working with such a talented team, and we are excited to significantly increase our investment to support their continued growth. We look forward to being part of their ongoing journey toward success.”
01
These are the top UK-based PR agencies for startups and scale-ups in 2025